Specifically, AAV6-PD-L1 lost its ability to mitigate arthritis when the dose decreased to 5x107 vg, whereas shPD-L1 continued to show efficacy (p <0.05) (Figures 2B, C). This evidence concerns the gene CD274 and arthritic joint disease.